Helen Mossop
Zoe Walmsley
Dr Nina Wilson
Dr Opeyemi Agbeleye
Michelle Bardgett
et al. | Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trials | 2025 |
|
Dr Faye Wolstenhulme
Irena Bibby
Mike Cole
Lydia Grixti
Dr Naomi McGregor
et al. | Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves' disease | 2024 |
|
Professor Timothy Cheetham
Mike Cole
Dr Mario Abinun
Dr Sonya Carnell
Jon Prichard
et al. | Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease | 2022 |
|
Dr Nilendran Prathalingam
Dr Louise Hyslop
Mike Cole
Daniel Cooney
Professor Mary Herbert
et al. | Developing a novel device, Eggcell, to improve temperature stability during oocyte collection for IVF | 2022 |
|
Dr Claire Wood
Mike Cole
Ruth Wood
Professor Simon Pearce
Professor Timothy Cheetham
| Initial response of young people with thyrotoxicosis to block and replace or dose titration thionamide | 2022 |
|
Dr Arthur Pratt
Dr Stefan Siebert
Mike Cole
Dr Deborah Stocken
Amy Cranston
et al. | Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial | 2021 |
|
Mike Cole
Professor Fai Ng
Dr Stefan Siebert
Dr Arthur Pratt
Professor John Isaacs
et al. | TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis | 2021 |
|
Dr Claire Wood
Mike Cole
Ruth Wood
Professor John Matthews
Professor Simon Pearce
et al. | Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis | 2020 |
|
Dr Stefan Siebert
Dr Arthur Pratt
Dr Deborah Stocken
Dr Miranda Morton
Amy Cranston
et al. | Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial | 2020 |
|
Mike Cole
Dr Ann Marie Hynes
Denise Howel
Dr Lesley Hall
Dr Mario Abinun
et al. | Adjuvant rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial | 2019 |
|
Professor Jeremy Parr
Dr Emma Todhunter
Professor Lindsay Pennington
Dr Deborah Stocken
Dr Jill Cadwgan
et al. | Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability | 2018 |
|
Professor Vinidh Paleri
Dr Joanne Patterson
Dr Deborah Stocken
Mike Cole
Professor Luke Vale
et al. | A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): study protocol | 2016 |
|
Dr Sarah Fordham
Mike Cole
Professor Julie Irving
Professor James Allan
| Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia | 2015 |
|
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Morton
et al. | PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia | 2015 |
|
Dr Sarah Fordham
Mike Cole
Professor Julie Irving
Professor James Allan
| Cytarabine leaves a mutational fingerprint in relapsing leukemia | 2014 |
|
